Jeff Ryckman: How many patients make it to CAR-T without ever seeing radiotherapy?
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University shared a post by David Russler-Germain on X/Twitter, adding:
”How many patients make it to CAR-T without ever seeing radiotherapy? Bet it’s the majority. Why aren’t we making noise about the 5-10% PFS benefits with appropriate use of cost effective RT? Is avoidance of toxic salvage therapy not a priority?”
Quoting the mentioned post by David Russler-Germain, Oncology Instructor at Siteman Cancer Center.
”CART cells are revolutionizing B-NHL treatment. But… Let’s not sweep under the rug:
(1) ~$400k product, ~$1M “total package”
(2) ~1/4 patients required ICU care
(3) Non-relapse mortality ~10%.
We need to acknowledge the downsides to make CART cells cheaper, faster, and safer.”
For the article click here.
Source: Jeff Ryckman/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023